How in vitro influences in silico utilized for the prediction of in vivo : pilot study of the drug-induced pro-arrhythmic potency prediction by Badyra, Bogna et al.
How in vitro influences in silico utilized  
for the prediction of in vivo — pilot study  
of the drug-induced pro-arrhythmic potency prediction
Bogna Badyra1,2, Bartosz Lisowski1,3, Sebastian Polak1,4, John Kudolo5,  
Barbara Wiśniowska1
1Unit of Pharmacoepidemiology and Pharmacoeconomics, Faculty of Pharmacy, Jagiellonian University Medical College, 
Kraków, Poland
2Department of Transplantation, Polish-American Institute of Pediatrics, Jagiellonian University Medical College, 
Kraków, Poland
3M. Smoluchowski Institute of Physics Jagiellonian University, Kraków, Poland
4 Simcyp (a Certara Company) Limited, Blades Enterprise Centre, John Street, Sheffield S2 4SU, UK
5Cytocentrics AG, Rostock, Germany
Corresponding author: Barbara Wiśniowska, Unit of Pharmacoepidemiology and Pharmacoeconomics, 
Faculty of Pharmacy, Jagiellonian University Medical College 
ul. Medyczna 9, 30-688 Kraków, Poland; E-mail: b.wisniowska@uj.edu.pl
Abstract: The current drug cardiac safety risk assessment paradigm is about to be changed. The discussed 
modifications cover clinical as well as pre-clinical sides. As for the latter, the pre-clinical assessment, it is 
planned to be based on the analysis of the drug-triggered multiple ion currents inhibition. Considering the 
variability in the in vitro patch clamp studies results, it would be of benefit to assess how these apparatus- 
and protocol-dependent differences influence the risk prediction and, eventually, the decision making. 
Four compounds, namely dextromethorphan, ketoconazole, terfenadine, and quinidine were screened for 
hERG inhibition with an automated patch clamp apparatus (CytoPatch™2). The results were then compared 
against the literature published data, and after being complemented with information about other current 
inhibitions and effective therapeutic plasma concentration, utilized for the in silico based safety assessment. 
Two endpoints were used: (1) the concentration dependent potential to induce early afterdepolarizations in 
the simulated action potential and (2) the arrhythmia-like disruption in the simulated pseudo-ECG signals. 
Data analysis results prove that IC50 values, describing the inhibition potential, significantly differ among 
studies, and the choice of input data can greatly influence the in silico based safety assessment and thus the 
decision making process.
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Introduction
A lot has been said and written recently about the drug induced pro-arrhythmic risk 
screening. The main reason for the activity is the currently proposed drug pro-arrhyth-
mic risk assessment modification [1, 2]. The intended changes cover all the main areas, 
beginning from the pre-clinical up to the clinical level. Proposed changes in the latter 
include the so-called thorough QT trials replacement with careful electrocardiography 
(ECG) evaluation in First-in-Human (FIH) studies using Exposure Response (ER) analysis 
in the evaluation of a drug’s effect on cardiac repolarization [3]. Despite criticism [4], 
first results prove that QT assessment, performed in early phase studies with the use of 
an intense ECG schedule and ER analysis, can detect a small QT effect with the same 
confidence as a thorough QT study [5, 6].
Comprehensive safety assessment of drugs requires examining the multiple in-
trinsic and extrinsic factors what influence cardiac rhythms. The generation of action 
potentials in cardiac cells requires coordination of multiple currents that are mediated 
by sodium, calcium, and potassium ion channels. Drug-triggered modification of any 
of these currents or their combination can either be pro- or anti-arrhythmic. There-
fore, at the pre-clinical level we cannot afford improper in vitro measurement. Proper 
assessment will be even more important with the MICE (multiple ion channel effects) 
initiative protocols introduced into the daily safety labs routine. Multiple channels 
multiplied by hundreds or thousands of compounds’ results in a substantial number of 
data points. 
These have to be generated, and what’s even more important, generated with a high 
quality assuring proper decision making [7, 8]. It is likely that such decisions will, at 
least partially, be made based on the basis of in silico simulations. The focus of these 
simulations will be the drugs pro-arrhythmic potency assessment [9].
These days automated patch clamp devices are believed to give an optimal trade-off 
between accuracy and economic considerations. They offer medium-to-high through-
put. Yet it should be clearly said that according to the well-known and often repeated 
expression “rubbish in, rubbish out” the in vitro data have to be of the highest possible 
quality, as even the best model will fail when improper data are provided. Often ne-
glected factors (like temperature, composition of bath solution, and voltage protocol) 
can significantly influence the results and therefore modify model output. 
Aims of the study
The ultimate aim of the cardiac-safety electrophysiological studies is to evaluate the 
pro-arrhythmic risk of a given compound based on the in vitro data, coming from ex-
periments performed in various conditions which were used to feed the in silico model 
of a human cardiac myocyte. During this study we intended to evaluate the usability of 
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the novel automated patch clamp method and apparatus (CytoPatchTM2) by testing our 
measurement results against previously published data on drug-induced ionic currents 
inhibition.
Materials and Methods
Drugs selection
The compounds were chosen following several criteria. Firstly, we wished to include 
drugs from various risk categories, based on the CredibleMeds classification [10]. This 
classification involves three main categories: known (Substantial evidence supports the 
conclusion that these drugs prolong the QT interval AND are clearly associated with a risk 
of TdP, even when taken as directed in official labeling), conditional/possible (Substantial 
evidence supports the conclusion that these drugs can cause QT prolongation BUT there 
is either insufficient evidence at this time that these drugs, when used as directed in offi-
cial labeling, are associated with a risk of causing TdP or risk appears only under certain 
conditions like excessive dose, hypokalemia, congenital long QT or by causing a drug-drug 
interaction that results in excessive QT interval prolongation) Torsade de pointes (TdP) 
risk and not listed (assumed as safe, with no arrhythmia reports). We looked at the 
availability of electrophysiological in vitro data describing other, apart from IKr, poten-
tially blocked currents. We also looked at the information about the pharmacokinetics, 
mainly the effective therapeutic plasma concentration (ETPC) and the protein binding 
(the so called fraction unbound). The final list of selected compounds with their brief 
characterization is given in Table 1.
Table 1. Compounds selected for the in vitro and in silico study.
Compound CredibleMeds classification Comments Ref.
Dextromethorphan
(DXM)
Not listed  
(considered  
as safe)
Considered as safe despite of relatively potent IKr 
inhibition. Metabolized by 2D6, plasma concentration 
and clinical effect will be CYP genetic polymorphic 
form dependent.
[22, 23]
Ketoconazole Conditional Risk of TdP
QT prolongation reported yet lack of known TdP cases 
during monotherapy. [24]
Terfenadine Known Risk  of TdP
Known as torsadogenic agent yet different mechanism 
as compared to quinidine. Considered as safe in 
physiological concentration, pro-arrhythmic potency 
significantly increases after CYP 3A4 inhibition (e.g. 
ketoconazole co-administration).
[24, 25]
Quinidine Known Risk  of TdP
Known as torsadogenic agent. Clearly pro-arrhythmic 
due to the mechanism of action. [26]
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In vitro study
Cell Culture. Stably transfected HEK 293 cells expressing the hERG ion channel (frozen 
Instant Cells, German Patent 10 2007 010 843.7-09, Cytocentrics Bioscience GmbH, 
Rostock, DE) were stored in liquid nitrogen. Each aliquot consisted of around 10 million 
cells. For use, the cells were thawed in extracellular buffer (EC) at room temperature 
(RT), centrifuged and re-suspended in EC. The cells were then moved to Cytocentrics 
Cell Reservoir, and used within 4 h.
Solutions and Drugs. The EC used for automated patch clamp recordings, thawing 
and resuspending of the HEK 293 cells, was composed of the following ingredients 
(in mM): 140 NaCl, 2.5 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES, 10 glucose and 15 sucrose. 
pH was adjusted to 7.4 ± 0.1 (NaOH); the osmolality was 320 ± 5 mOsm/kg. The buffer 
was stored at 4oC, degassed and pre-warmed to RT prior to use. The intracellular buffer 
(IC) used for automated patch clamp recordings was provided by Cytocentrics Bioscience 
GmbH, Rostock, DE. It was composed of the following ingredients (in mM): 100 KGluconat, 
20 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 11 EGTA-KOH, 4 MgATP, 3 phosphocreatine- 
Na2-H2O, and 9 sucrose. pH was 7.2 ± 0.1; the osmolality was 295 ± 5 mOsm/kg. Ali-
quots were stored at –20oC, thawed prior to use, and used for maximum 4 h. All drugs 
were purchased from Tocris Biosciences. Stock solutions were prepared in DMSO for 
all compounds in concentrations as follows: quinidine 100 mM, ketoconazole 50 mM, 
dextromethorphan (DXM) 50 mM and terfenadine 100 mM. Aliquots of these stock solu-
tions were stored in –20oC. For electrophysiological recordings working concentrations 
of the drugs were freshly prepared by diluting to respective millimolar concentrations 
in DMSO and then to micromolar concentrations in EC. Obtained working solutions 
were used for no more than 4 hours. Final concentration of DMSO did not exceed 0.1%.
Electrophysiological recording. Experiments were performed on automated patch-
clamp device CytoPatchTM2 (Cytocentrics Bioscience GmbH, Rostock, DE), according 
to a protocol described in [11]. In short, silicon dioxide microfluidic chips were used 
with two embedded quartz pipette tips (2 mm in diameter), each surrounded by a Cy-
tocentering channel for capture and coordination of cells out of the cell suspension and 
to the pipettes. This setup allows for simultaneous seal formation and recordings in two 
cells. The sequence to whole-cell configuration (i.e. chip filling, cell capture, gigaseal 
formation, and patch rupture) was fully automated.
hERG outward tail currents were measured by executing the following pulse proto-
col every 10 s: from a holding potential of −70 mV, cells were voltage-clamped for 100 
ms to −50 mV and then for 2 s to +40 mV. To evoke outward tail currents, a 2 s step 
to −50 mV followed (see Fig. 1 for illustration). The peak tail current was corrected for 
the leak current determined during the first short voltage step to −50 mV. After that, 
the temperature was increased from room to physiological one (36 ± 1oC) using a pro-
grammable Chipholderblock Temperature Controlling Unit.
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The cells were then continuously perfused with EC for up to 6 minutes to establish sta-
ble pre-drug recordings. After this control phase, drug solutions were continuously applied 
to the cell via the transport channel for 5 (non-sticky compounds) or for 8 (terfenadine) 
minutes [12].
Exemplary traces presenting the effects of tested compounds on hERG currents and 
the voltage protocol are presented in Figure 1.
Data analysis and statistical procedures
Up to three increasing concentrations of the same compound were applied to one cell. 
Only those cells with a stable whole-cell membrane resistance of more than 500 MOhm 
and a hERG tail current amplitude of at least 300 pA were used for analysis. hERG tail 
currents were averaged over 50 s at the end of the control phase and the end of each 
application phase. Current inhibition was calculated by dividing the mean tail current 
in the presence of the drug by the mean tail current of the control phase. All measure-
ments were taken at physiological temperature.
(B)
–70 mV
–50 mV
1 M Ketoconazole
Control
40 mV
–50 mV
–70 mV
0.1 M Terfenadine
Control
5 M DXM
Control
(A)
1 M Quinidine
Control
200 pA 200 pA
300 pA
500 pA
Fig. 1. Sample effects of tested compounds on hERG currents. For each drug, the control current before drug 
administration is shown in black and the final effect of the drug is shown in red (A). The voltage protocol is 
depicted below (B).
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For calculation of the concentration-response relationships for the inhibition of hERG 
peak tail current amplitudes, tested drugs were studied at the following concentrations: 
0.1, 0.5, 1, 5, and 10 µM for quinidine; 0.1, 1, 5, and 10 µM for ketoconazole; 0.5, 1, 5, 
and 10 µM for dextromethorphan; 0.003, 0.03, 0.1, and 0.3 µM for terfenadine. The 
number of observations ranged from 3 to 7 per test concentration. 
Dose-response relationships for each drug were determined by fitting the inhibition 
of peak tail current amplitudes caused by a concentration C of a given compound, I(C), 
to the Hill equation (MATLAB R2014a curve-fitting toolbox; MathWorks; Nonlinear 
Least Squares method and Trust-Region algorithm):
 
I(C) =          100
                   1 + (IC50/C)
n
where IC50 is the median inhibitory concentration (concentration of a drug that causes 
50% current inhibition) and n is the slope parameter (Hill coefficient). Figure 2 shows 
the obtained results and fitted Hill plots.
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Fig. 2. Fitted dose-response curves (solid lines) and experimentally obtained data (points). Four compounds 
were tested: quinidine (A), dextromethorphan (B), ketoconazole (C) and terfenadine (D). Error bars show 
the standard deviation.
Bogna Badyra, Bartosz Lisowski, et al.
11
In silico study
The Cardiac Safety Simulator (CSS) is a tool for in vitro-in vivo extrapolation of the 
cardiac effects of drugs [2]. The CSS platform allows for the evaluation of the influence 
of multiple ion channels inhibition on the human left ventricular cardiomyocyte, and 
then on the cell string of connected cells, which is supposed to mimic the heart wall. 
The simulated outputs include the action potential (AP), the pseudo-ECG and their de-
rivatives: (1) the APD50 (time needed to reach 50% of repolarization) and the APD90 
(time needed to reach 90% of repolarization) for the action potential and (2) the QT, 
the QRS, the J-Tpeak, and the Tpeak-Tend for the ECG level. The O’Hara-Rudy mod-
el, a mathematical description of the electrophysiology of epicardial, endocardial and 
midmyocardial (M) cells, was utilized during the described study [13].
Table 2. In vitro inhibition data utilized during the simulation study.
Compound Value
IKr IKs INa ICaL
IC50 n Ref. IC50 n Ref. IC50 n Ref. IC50 n Ref.
Quinidine
reference_1 0.33 0.74 [15]
44 1* [27] 14.6 1.22 [14] 6.4 0.68 [14]
reference_2 0.72 1 [14]
Ketoconazole reference_1 1.7 0.9 [28] – – – – – – – – –
DXM reference_1 5.1 1.02 [29] – – – – – – – – –
Terfenadine
reference_1 0.0066 1* [30]
4.4 1* [31] 2 1.81 [15] 0.93 1.8 [15]
reference_2 0.05 1.15 [15]
Midmyocardial (M) cells are the most sensitive to disruption of ionic current and 
it was these cells that were used for simulations on the single cell level. Simulation was 
run until the steady state and the last 12 seconds were considered sufficiently stable to be 
analyzed. The raw traces were further analyzed for the early afterdepolarization (EAD) 
presence, as EADs have been proposed as the potential pro-arrhythmic risk surrogates [9]. 
The second arm of the study was based on the pseudo-ECG simulation. A heteroge-
neous string of cells was put together with 20% of them coming from the epicardium, 
30% from the midmyocardium (M) and the rest (50%) from the endocardium. For 
a one-dimensional string of cells the forward Euler method was used to integrate model 
equations and the results were then used to calculate a pseudo-ECG. 
The space step and the time step were by default set to ∆x = 0.01 mm and ∆t = 0.01 s, re-
spectively. Physiological parameters describing the virtual individual included plasma ions 
concentration (K+ = 4.06 mM, Na+ = 132.55 mM, Ca2+ = 2.23 mM) and parameters describ-
* assumed as 1 due to the lack of information in the respective reference source
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ing cardiomyocytes (volume = 6591 µm3, area = 1766 µm2, electric capacitance = 46.9 pF 
and sarcoplasmic reticulum volume = 395.5 µm3). Heart wall thickness (i.e. string length) 
was set to 11 mm. Heart rate value was set to 60 min-1 (RR = 1000 ms).
Apart from the in-house measured hERG inhibition values, simulations were run 
separately for different sets of the in vitro inhibition data, as presented in Table 2.
The literature offers multiple IC50 values from multiple sources for quinidine and ter-
fenadine. We tested those coming from the same study, done by Kramer et al. [14]. We 
have also considered the lowest known to us IC50 value from ref. [15]. For ketoconazole 
two IC50 values were tested. The first one was obtained in experiment carried out in the 
most physiological conditions (temperature, ions bath concentrations, voltage proto-
col). The second IC50 value was the lowest found. There was only one study available 
for dextromethorphan.
Literature derived IC50 values for the hERG channel obtained at room temperature 
were further scaled to the physiological conditions with the use of inter-system extrap-
olation factors [16].
IC50 values were normalized by the largest found free effective therapeutic plasma 
concentration (ETPCunbound), as presented in Table 3. It was assumed that the plasma 
concentration is equal to the one at the site of action (ion channel in the heart tissue) 
and the exposure during simulation studies reached 0 (control), 1, 3, 5, 10, 30, 50, 100, 
300, 500, and 1000 times that of ETPCunbound.
Table 3. Literature derived free effective therapeutic plasma concentration (ETPCunbound) utilized during 
the simulation study.
Compound ETPCunbound Description Ref.
Quinidine 0.9–3.2 – [14, 32]
Ketoconazole 0.025–0.19 – [14, 32]
DXM
0.008–0.0217
0.298–0.851
Extensive metabolizers (EM)
Poor metabolizers (PM)
[33]
Terfenadine
0.0001–0.00029
0.003–0.008
Without 3A4 inhibition
With strong 3A4 inhibition
[14, 32]
The obtained pseudo-ECGs are presented as the logarithm of the ratio ETPCbaseline/
ETPCthreshold, where ETPCbaseline is the highest free therapeutic ETPC as shown in Table 3, 
and ETPCthreshold is the lowest free concentration for which a clear arrhythmic signal ap-
pear. The higher the ratio’s value, the lower the arrhythmia risk (higher concentration 
is needed to trigger cardiac event). Conversely, the lower the ratio, the higher the risk 
of an irregular ECG signal.
All simulations were carried out on a laptop PC with 8Gb RAM and an Intel i5 CPU. 
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Results
The internally obtained IC50 and Hill coefficient (n) values for all tested drugs are pre-
sented in Table 4.
Table 4. IC50 values and Hill coefficients (n) calculated for the concentration-dependent inhibition of hERG 
peak tail currents by studied compounds in HEK 293 cells.
Compound IC50 [µM] Hill coefficient
Quinidine 1.01 1.00
Ketoconazole 0.47 0.80
DXM 6.27 1.09
Terfenadine 0.07 0.96
They were compared against literature reported values obtained in similar conditions 
for major parameters (cell model, patch clamp technique), yet with significant differences 
in the experimental protocol (voltage protocols, ion concentrations, temperature, etc.). 
Results of such comparison are presented below (Table 5, Fig. 3).
In house
Paul et al.
Kramer et al.
Wible et al.
Ducrocq et al.
Okada et al.
Perrin et al.
Xia et al.
In house
Martin et al.
Kramer et al.
Friemel et al.
Wible et al.
Perrin et al.
Okada et al.
In house
Ridley et al.
Chiu et al.
In house
Deisemann et al.
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Fig. 3. Dose-response curves for quinidine (a), dextromethorphan (b), ketoconazole (c) and terfenadine (d) 
for data from Table 4.
How in vitro influences in silico utilized for the prediction of in vivo...
14
Ta
bl
e 
5.
 R
ep
re
se
nt
at
iv
e 
lit
er
at
ur
e 
de
riv
ed
 a
nd
 in
 h
ou
se
 m
ea
su
re
d 
hE
RG
 in
 v
itr
o 
in
hi
bi
tio
n 
da
ta
 fo
r f
ou
r t
es
te
d 
co
m
po
un
ds
.
C
om
po
un
d
Re
fe
re
nc
e
Se
tu
p
C
el
l
IC
50
 
[μ
M
]
H
ill
  
co
effi
ci
en
t
Te
m
pe
ra
tu
re
K
+ 
ba
th
 
[m
M
]
t1
 p
ul
se
 
[s
]
t2
 p
ul
e 
[s
]
Q
ui
ni
di
ne
In
 h
ou
se
C
yt
oP
at
ch
H
EK
1.
01
1.
00
P
2.
5
2
2
Pa
ul
 et
 a
l. 
[3
4]
M
an
ua
l
H
EK
0.
41
0.
76
P
4
0.
5
0.
5
K
ra
m
er
 et
 a
l. 
[1
4]
Q
pa
tc
h 
or
 
Pa
tc
hX
pr
es
s
H
EK
0.
72
1.
06
R
4
2
2
W
ib
le
 et
 a
l. 
[3
5]
M
an
ua
l
H
EK
1.
07
1
R
N
A
2
2
D
uc
ro
cq
 et
 a
l. 
[1
5]
M
an
ua
l
H
EK
0.
33
0.
74
R
4
1
1
O
ka
da
 et
 a
l. 
[3
6]
Q
pa
tc
h
C
H
O
0.
63
8
1.
01
2
R
4
2
2
Pe
rr
in
 et
 a
l. 
[3
7]
M
an
ua
l
C
H
O
3.
2
0.
8
R
5
3
0
X
ia
 et
 a
l. 
[3
8]
M
an
ua
l
C
H
O
2.
1
1
R
4
2
1
Ke
to
co
na
zo
le
In
 h
ou
se
C
yt
oP
at
ch
H
EK
0.
47
0.
8
P
2.
5
2
2
Ri
dl
ey
 et
 a
l. 
[2
8]
M
an
ua
l
H
EK
1.
7
0.
9
P
4
2
4
C
hi
u 
et
 a
l. 
[3
9]
M
an
ua
l
H
EK
1.
92
1.
46
P
4
0.
5
0.
5
D
X
M
In
 h
ou
se
C
yt
oP
at
ch
H
EK
6.
27
1.
09
P
2.
5
2
2
D
ei
se
m
an
n 
et
 a
l. 
[2
9]
M
an
ua
l
C
H
O
6.
5
1.
2
R
5.
4
2
2
Te
rf
en
ad
in
e
In
 h
ou
se
C
yt
oP
at
ch
H
EK
0.
07
0.
96
P
2.
5
2
2
M
ar
tin
 et
 a
l. 
[4
0]
M
an
ua
l
H
EK
0.
01
6
0.
83
P
5
3
4
K
ra
m
er
 et
 a
l. 
[1
4]
Q
pa
tc
h 
or
 
Pa
tc
hX
pr
es
s
H
EK
0.
05
1.
15
R
4
2
2
Fr
ie
m
el
 et
 a
l. 
[4
1]
M
an
ua
l
H
EK
0.
02
77
1.
13
R
5.
6
2
2
W
ib
le
 et
 a
l. 
[3
5]
 
M
an
ua
l
H
EK
0.
00
8
1
R
 N
A
2
2
Pe
rr
in
 et
 a
l. 
[3
7]
M
an
ua
l
C
H
O
0.
06
41
1.
2
R
5
3
0
O
ka
da
 et
 a
l. 
[3
6]
Q
pa
tc
h
C
H
O
0.
09
85
2
1.
17
6
R
4
2
2
Bogna Badyra, Bartosz Lisowski, et al.
15
Table 5 shows representative literature and in-house data on tested compounds. 
Experimental setup (manual or automated patch clamp), cell model (HEK or CHO), 
conditions (temperature and K+ ion concentration), and pulse protocols are presented 
for results with highlighted IC50 and Hill coefficient (n) values. P and R stand for phys-
iological and room temperature, respectively.
Figures 4A and B present log(ETPCbaseline/ETPCthreshold) values for all tested drugs 
with the proposed safety thresholds separating three risk classes: safe, conditional and 
Fig. 4. Log values of the ETPCbaseline/ETPCthreshold ratios for four tested drugs with the proposed safety 
thresholds separating three risk classes (A — single cell based simulations and B — pseudoECG).
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high risk for the single cell levels and the pseudo-ECG, respectively. It is worth noting 
that the predicted risk classification depends on the IKr IC50 values and on the active 
concentrations used during the simulation study.
Discussion
As it was previously stated, the aim of the electrophysiological studies done for the 
purpose of drug cardiac safety assessment is to evaluate the pro-arrhythmic risk. There 
are multiple factors contributing to the clinically observed, and potentially life-threat-
ening, cardiac arrhythmias [17]. Obviously, not all those factors can be experimentally 
tested at the pre-clinical stage. This is why in silico modeling has become such a popular 
tool for assessing drug toxicity. By measuring only a small set of in vitro parameters 
(e.g. dose-response relations) and, next, combining them with pharmacokinetic param-
eters (e.g. ETPC) and system data (human physiology description) it is possible to gain 
insights into phenomena as complex as the electrical activity of cardiac cells. Even the 
best theoretical model will fail when fed with biased parameters. 
The open question is often which parameters are “biased” and which are “accurate”. 
Figure 3 clearly shows that even the most basic information on drug-cell interaction, 
i.e. ion channel inhibition, significantly differs among studies. Dose-response relations 
obtained from electrophysiological recordings are extremely sensitive to experimental 
procedures and conditions. Recently, more and more effort has been put into unifying 
the procedures but still a lot needs to be done [12, 18].
Another question is about using average values that are obtained by either single 
groups on different in vitro setups (e.g. for various temperature conditions or cell types 
or apparatus) or by different groups that use distinct protocols and equipment. Only 
large-scale initiatives, bringing together different laboratories for testing the same drug 
effects in unified conditions, but on different devices, may give insight into the sources 
of diversity seen in the literature. This is one of the aims of the CIPA initiative [19].
It is imperative that as many conditions as possible are reported in the Methods 
section for all published reports. Some of them are obvious, like the cell type, tempera-
ture, buffer composition and pulse protocols. Others, like the algorithm used to fit the 
data to the Hill plot or the precise value of not only the IC50, but also the correspond-
ing Hill coefficient, are very often skipped. This makes comparison between datasets 
impossible. Other parameters that vary between groups are the time of cell incubation 
with the drug and the time of current recording after drug administration. Especially 
in automated patch clamp those parameters can greatly affect final results. Simulation 
studies done with the use of in vitro measured values show that the compound specific 
risk classification may depend on them. In our case this is clearly seen for terfenadine 
for which proper pro-arrhythmic potency assessment requires thorough analysis. This is 
because it depends on complex pharmacokinetics (metabolism mainly via cytochrome 
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P450 3A4) and biological activity (multiple channels inhibition). Terfenadine is a very 
potent IKr current inhibitor but its biotransformation triggered by the CYP3A enzyme 
is close to complete in physiological conditions. The first pass metabolism effects in 
very low systemic concentration of the parent compound but clinically relevant con-
centration of its main metabolite — fexofenadine which has no effect on the cardiac 
cells membrane potential and QT interval. Therefore when considered as single drug 
it should be classified as safe (what is the case for Reference_2 and In house IC50 val-
ues but not Reference_1 which over-predicts the risk), whereas for high concentration 
which can be achieved for example after concomitant exposure to CYP3A4 inhibitors 
(like ketoconazole) the risk increases what was properly picked-up by simulation done 
with Reference_1 value as presented in Figure 3. Four substances tested in the current 
study, although covering a relatively wide range of mechanisms and inhibition activity 
against various ionic channels, do not allow for the drawing of strong conclusions. We 
note that in this study we did not attempt to include active metabolites effects or phys-
iological and pathophysiological parameters. Computational power and achievements 
in the modeling and simulation of cardiac physiology currently allow for in silico drug 
safety testing at the population rather than individual level [20, 21]. Another step would 
be to account for both sources of uncertainty in the cardiac risk prediction — in vitro 
and physiological factors.
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